On Rotation: November 2025

The year is coming to an end, and companies are rushing to get the right leadership in place for 2026.

But who has gone where? Amid all the other end-of-year wrap-up tasks you’re occupied with, it can be hard to keep track of who’s in charge of what now.

That’s where we come in! We publish a monthly noncomprehensive roundup of leadership changes everywhere from startups to market-leading mega corporations. (Without giving too much away, it was a busy month for current and former FDA leadership.)

Welcome to November’s On Rotation.

Have a job announcement to share? Drop Caroline an email at [email protected].

Deb Autor. The former FDA deputy commissioner of global regulatory operations and policy is now the inaugural chief policy officer at direct-to-consumer company Hims & Hers, the company announced on Nov. 17. The role’s creation comes as the FDA ramps up rules about drug advertising; Hims & Hers was one of many advertisers to get a warning letter in September.

Amy Flaster. Same title, bigger job. Flaster became chief medical officer of the Cigna Group, effective Nov. 1. She serves the company’s insurance arm, Cigna Healthcare, and Evernorth, its pharmacy and specialty care division. Before this, she was chief medical officer of only Cigna Healthcare.

Scott Gottlieb. The FDA’s former head (2017–2019) joined UnitedHealth Group’s board of directors on Nov. 18.

Mala Murthy. Virtual care provider Teladoc Health said goodbye to Murthy as its CFO on Nov. 21. She left to “pursue an opportunity outside of the healthcare industry,” per an Oct. 23 press release from the company, which is still searching for a replacement. She was Teladoc’s CFO for over six years and came to the company after working at American Express and PepsiCo.

Richard Pazdur. After 26 years at the FDA, Pazdur became director of its Center for Drug Evaluation and Research on Nov. 11, and hopefully he lasts longer than the three other people who held that position this year. The most recent before Pazdur was George Tidmarsh, who resigned Nov. 2 amid an investigation of whether he misused his power. Tidmarsh reportedly said the investigation was retaliation for his concerns about a new drug review program.

Kaya Pai Panandiker. New York-based biopharma LB Pharmaceuticals, a startup focused on treatments for neuropsychiatric diseases, announced Panandiker as its chief commercial officer on Nov. 12. She previously held the same position at Massachusetts-based biotech Neumora.

Vignesh Rajah. Global specialty pharmaceutical company SERB Pharmaceuticals announced Rajah as its new chief medical officer on Nov. 17. He most recently held the same title at Princeton, New Jersey-based US biotech Y-mAbs Therapeutics, which SERB officially acquired in September.

Arjun Srinivasan. Joint Commission, an independent nonprofit that reviews and accredits healthcare organizations, announced Nov. 10 it had nabbed Srinivasan as its new deputy chief medical officer. Srinivasan left the CDC after 22 years before taking this role.

Kyle Zebley. The American Telemedicine Association (ATA), a nonprofit with 400+ member organizations, is getting a new CEO. Current CEO Ann Mond Johnson will retire Dec. 10 after eight years in the role, and Zebley—currently ATA’s SVP of public policy and executive director of advocacy org ATA Action—will take her place, the group announced Nov. 10.